



## Total Voting Rights

January 2, 2024 9:23 AM EST

RNS Number : 3554Y  
MaxCyte, Inc.  
02 January 2024

**MaxCyte, Inc.**

("MaxCyte" or the "Company")

### Total Voting Rights

**ROCKVILLE, MD, January 2, 2024** - MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, announces that pursuant to its block admission facility, since 30 November 2023 it has issued 251,799 of common stock, \$0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.

#### Total voting rights

As at 31 December 2023, the total issued stock capital of the Company following the recent issue of the new Common Stock is 103,961,670 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

For further information, please contact:

#### **MaxCyte Contacts:**

##### ***US IR Adviser***

**Gilmartin Group**

David Deuchler, CFA

+1 415-937-5400

[ir@maxcyte.com](mailto:ir@maxcyte.com)

##### ***Nominated Adviser and Joint Corporate***

##### ***Broker***

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

##### ***UK IR Adviser***

##### **ICR Consilium**

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

[maxcyte@consilium-](mailto:maxcyte@consilium-comms.com)

[comms.com](mailto:maxcyte@consilium-comms.com)

#### **About MaxCyte**

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the

rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](https://maxcyte.com) and follow us on [Twitter](#) and [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRQKBBBCBKKKDK